CSL - Operating Profit

Stock Price
139.37
Daily Change
-1.78 -1.26%
Monthly
-9.61%
Yearly
-44.32%
Q1 Forecast
138.07

CSL reported $2.64B in Operating Profit for its fiscal semester ending in December of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Arca Biopharma USD -25.09M 5.23M Mar/2025
aTyr Pharma USD -26.74M 6.43M Sep/2025
Bio Path USD -3.24M 616K Mar/2025
Brainstorm Cell Therapeutics USD -3.09M 100K Mar/2025
Cara Therapeutics USD -2.39M 3.49M Mar/2025
CSL USD 2.64B 1.97B Dec/2025
Curis USD -12.51M 40K Jun/2024
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Immunic USD -25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024